Drug Profile
NMS E194
Alternative Names: NMS-E194Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Class Antineoplastics; Arylsulfonates; Sulfonamides
- Mechanism of Action EIF 2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in Italy (PO)
- 01 Apr 2017 Preclinical trials in Multiple myeloma in Italy (PO)
- 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)